Matinas BioPharma Holdings (MTNB) Non-Current Assets (2013 - 2026)
Matinas BioPharma Holdings (MTNB) posted quarterly Non-Current Assets of $3.1 million for Q1 2026, down 31.84% year-over-year from $4.5 million in Q1 2025, and down 2.36% quarter-over-quarter from $3.1 million in Q4 2025.
Matinas BioPharma Holdings (MTNB) Non-Current Assets (2013 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Non-Current Assets for 14 consecutive years, with $3.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets fell 31.84% year-over-year to $3.1 million; the TTM figure through Mar 2026 stood at $3.1 million (down 31.84% YoY), while the FY2025 annual figure was $3.1 million, down 32.13% from the prior year.
- Non-Current Assets slipped to $3.1 million in Q1 2026 per MTNB's latest filing, from $3.1 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $10.7 million in Q1 2022 and bottomed at $3.1 million in Q1 2026.
- Historically, Non-Current Assets has averaged $7.8 million across 5 years, with a median of $9.3 million in 2024.
- Annual changes were most pronounced in 2022 — Non-Current Assets increased 16.16% — and 2025, when it slumped 54.26%.
- Matinas BioPharma Holdings' Non-Current Assets stood at $10.3 million in 2022, then retreated by 7.06% to $9.6 million in 2023, then slumped by 51.72% to $4.6 million in 2024, then sank by 32.13% to $3.1 million in 2025, then slipped by 2.36% to $3.1 million in 2026.
- Business Quant data shows MTNB's Non-Current Assets at $3.1 million in Q1 2026, $3.1 million in Q4 2025, and $4.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Matinas BioPharma Holdings | 1.19 Mn | 375,426.61 | - | 2.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.27 Mn |
| Mar 31, 2026 | 3.06 Mn |
| Dec 31, 2025 | 3.13 Mn |
| Sep 30, 2025 | 4.04 Mn |
| Jun 30, 2025 | 4.16 Mn |
| Mar 31, 2025 | 4.49 Mn |
| Dec 31, 2024 | 4.62 Mn |
| Sep 30, 2024 | 8.84 Mn |
| Jun 30, 2024 | 9.08 Mn |
| Mar 31, 2024 | 9.32 Mn |
| Dec 31, 2023 | 9.56 Mn |
| Sep 30, 2023 | 9.80 Mn |
| Jun 30, 2023 | 10.03 Mn |
| Mar 31, 2023 | 10.06 Mn |
| Dec 31, 2022 | 10.29 Mn |
| Sep 30, 2022 | 10.45 Mn |
| Jun 30, 2022 | 10.49 Mn |
| Mar 31, 2022 | 10.67 Mn |
| Dec 31, 2021 | 10.33 Mn |
| Sep 30, 2021 | 10.50 Mn |